<DOC>
	<DOC>NCT00503386</DOC>
	<brief_summary>The purpose of this study is to determine whether palonosetron is tolerate and effective in preventing chemotherapy-induced nausea and vomiting in oriental population. The study is comparing the safety and efficacy of palonosetron with granisetron, a frequently used antiemetic in China.</brief_summary>
	<brief_title>Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Male or female, age ≥ 18 yrs and ＜70 yrs with histologically or cytologically confirmed Malignant disease Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60 Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60 ~ 80 mg/m2 on study Day 1 Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit Patients with hepatic, renal, or cardiovascular impairment eligible at the investigator's discretion Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible at the investigator's discretion Predicted life expectancy of ≥ 3 months Provision of written informed consent. Inability to understand or cooperate with study procedures Receipt of investigational drugs ≤ 30 days before study entry Receipt of other investigational drugs during the course of this study Seizure disorder or any condition requiring anticonvulsants, sedatives CNS malignancy or metastasis Ongoing emesis due to obstruction of digestive tract Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy Moderate or severe nausea and vomiting after any previous chemotherapy Scheduled receipt of any chemotherapeutic agent with an emetogenicity level ＞3 during study Days 25 Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 25 Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of study initiation and throughout day 5 Contraindications to 5HT3 receptor antagonists Contraindications to chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>chemotherapy-induced nausea and vomiting</keyword>
	<keyword>acute</keyword>
	<keyword>delayed</keyword>
	<keyword>emesis</keyword>
	<keyword>antiemetics</keyword>
	<keyword>5-HT3 receptor antagonist</keyword>
	<keyword>granisetron</keyword>
	<keyword>palonosetron</keyword>
</DOC>